SECAUCUS, N.J., May 7, 2026
Pierre Fabre Pharmaceuticals (PFP) announced a significant regulatory update following a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for tabelecleucel, an investigational allogeneic T-cell immunotherapy developed for patients with relapsed/refractory Epstein-Barr Virus positive post-transplant lymphoproliferative disease (R/R EBV+ PTLD). The company stated that it has aligned with the FDA on a potential pathway for BLA resubmission, marking an important milestone in efforts to bring the therapy to patients facing a rare and life-threatening lymphoma with no FDA-approved treatment options currently available.
Pierre Fabre emphasized that the disease remains an urgent unmet medical need because survival for patients with relapsed or refractory EBV+ PTLD is often measured in weeks or months after failure of standard therapies, including anti-CD20 regimens. Company executives noted that the FDA meeting represented a productive step toward advancing regulatory review and clarifying requirements for resubmission of the application.
FDA Supports Single-Arm Study Approach for BLA Resubmission
According to Pierre Fabre Pharmaceuticals, the FDA agreed during the Type A meeting that a single-arm clinical study using an appropriate historical control could potentially serve as an adequate and well-controlled study to support safety and efficacy evaluation for the proposed indication. The company said this agreement may provide a viable regulatory framework for advancing the tabelecleucel application toward future review.
As part of the proposed resubmission strategy, Pierre Fabre plans to submit updated clinical datasets including additional patients and longer-term follow-up data from the pivotal Phase 3 ALLELE study, which evaluated tabelecleucel in both adults and children aged two years and older with relapsed or refractory EBV+ PTLD following solid organ transplant or hematopoietic cell transplant. The company also intends to provide supportive data as part of the revised regulatory package.
Advertisement
Industry analysts say the FDA’s willingness to consider historical-control methodology reflects increasing regulatory flexibility for ultra-rare diseases where randomized controlled trials may be difficult due to limited patient populations and severe disease burden. Researchers believe cell therapies targeting EBV-associated lymphomas could represent an important advancement for transplant-related oncology care.
Tabelecleucel Targets Rare and Aggressive Post-Transplant Lymphoma
EBV+ PTLD is a rare but potentially fatal complication that can occur after organ transplantation or hematopoietic stem cell transplantation when immune suppression allows uncontrolled proliferation of Epstein-Barr virus-infected lymphocytes. Current treatment approaches often involve reduction of immunosuppression, rituximab-based therapy, chemotherapy, or experimental interventions, but treatment outcomes remain poor for many refractory patients.
Tabelecleucel is an allogeneic T-cell therapy designed to target EBV-infected cells while offering a potentially off-the-shelf immunotherapy approach for patients with few remaining therapeutic options. Cell-based immunotherapies continue attracting major investment within oncology and rare disease sectors due to their potential to selectively target cancer-associated cellular mechanisms while reducing systemic toxicity compared with conventional chemotherapy.
Pierre Fabre Pharmaceuticals stated that innovation remains central to its long-term strategy in oncology and rare diseases, with additional pipeline programs targeting NRAS-mutant melanoma, MET-driven non-small cell lung cancer, and X-linked hypohidrotic ectodermal dysplasia (XLHED).
Cell Therapy Development Continues Expanding Globally
The regulatory update underscores the continued expansion of the global cell and gene therapy market, particularly in oncology indications with high unmet medical need. Experts believe regulatory agencies worldwide are increasingly adopting adaptive review approaches for innovative therapies targeting rare diseases where conventional study designs may not always be feasible.
As the oncology sector continues shifting toward precision medicine and immune-based therapies, companies developing advanced biologics, T-cell therapies, and personalized oncology platforms are expected to remain at the forefront of next-generation cancer treatment innovation. Positive regulatory progress for tabelecleucel could strengthen confidence in future allogeneic immunotherapy development programs targeting rare hematologic malignancies and transplant-associated cancers.
Source: Pierre Fabre Pharmaceuticals press release
